Bharat Biotech’s intranasal vaccine cleared for ‘restricted emergency use for 18+’, efficacy data not released

The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops, a press release said.